Business EconomyPosted at: Oct 14 2025 12:14AM


Bristol Myers Squibb launches Kopozgo in India for treatment of symptomatic Obstructive Hypertrophic Cardiomyopathy

Hyderabad, Oct 13 (UNI) Bristol Myers Squibb (BMS) today announced the launch of Kopozgo® (Mavacamten) in India -- the first and only oral, selective cardiac myosin inhibitor approved in the country for the treatment of adults with symptomatic New York Heart Association (NYHA) Class II–III obstructive hypertrophic cardiomyopathy (OHCM).
Symptomatic obstructive HCM is an often-inherited heart disease that can be a chronic, debilitating and progressive condition where patients may experience symptoms of shortness of breath, dizziness and fatigue as well as serious, life-altering complications, including heart failure, arrhythmias, stroke and in rare cases (~1%) sudden cardiac death.
It affects about 1 in 500 people worldwide, and it is estimated that as many as 2.8 million people in India may be living with the condition; however, 80-90 % patients remain undiagnosed.
Existing medical treatments in India, such as beta blockers, calcium channel blockers, and disopyramide, reduce symptoms but do not address the underlying cause.
Kopozgo is the first in-class disease-specific treatment targeting the core pathophysiological mechanism of obstructive HCM, leading to improvement in functional capacity of heart and symptoms.
Mavacamten was approved by the Central Drugs Standard Control Organisation (CDSCO) with an import license issued on March 6, 2025.
Kopozgo is now available to patients in India.
The approval of Kopozgo in India is based on positive efficacy and safety results from two Phase III clinical trials, EXPLORER-HCM and VALOR-HCM.
Sanjay Sharma, General Manager and Managing Director, BMS India, mentioned, “With the launch of Kopozgo in India, patients with oHCM now have a promising first-in-class treatment option. This breakthrough brings hope to individuals and families facing this condition, giving clinicians a novel therapy to address the unmet need in treatment. Bristol Myers Squibb is committed to advancing cardiovascular care for patients in India.”
Globally, mavacamten has been widely recognized, with its first approval granted by the U.S. Food and Drug Administration (FDA) on April 28, 2022, followed by approval from the European union on June 26, 2023.
Since then, the medicine has continued to expand its reach, receiving marketing authorization in more than 50 countries, underscoring its global significance as a breakthrough therapy for symptomatic obstructive hypertrophic cardiomyopathy. UNI KNR SS
Please log in to get detailed story.
Tags: #Bristol Myers Squibb launches Kopozgo in India for treatment of symptomatic Obstructive Hypertrophic Cardiomyopathy
More News

HIPLEX 2026 to showcase latest plastics technologies in Hyderabad from Aug 7

14 Jul 2026 | 9:14 PM

Hyderabad, July 14 (UNI) The Telangana and Andhra Plastics Manufacturers Association (TAAPMA) will organise HIPLEX 2026, one of India's largest international plastics exhibitions, at the HITEX Exhibition Centre here from August 7 to 10.

see more..

Stock Markets end in red led by surge in crude oil prices, weak global cues

14 Jul 2026 | 7:36 PM

New Delhi, July 14 (UNI) The Indian Stock Markets on Tuesday ended sharply lower led by a surge in crude oil prices following escalating tensions and weak global market cues.

see more..

Xebia launches AI-ready data platform Xebia Axis

14 Jul 2026 | 6:09 PM

Bengaluru, July 14 (UNI) Xebia, a global AI-first digital transformation and engineering company, on Tuesday launched Xebia Axis: Agentic Data Foundation, a platform aimed at helping enterprises modernise their data infrastructure and accelerate artificial intelligence (AI) adoption.

see more..

Aditya Birla group to buy Shell's Sprng Energy for Rs 17,200 cr

14 Jul 2026 | 6:05 PM

Mumbai, July 14 (UNI) Aditya Birla Renewables Limited (ABRen), a subsidiary of Grasim Industries Ltd has officially announced the signing of a definitive agreement to acquire 100% equity shares and securities of Solenergi Power Private Limited, which owns the Sprng Energy group of companies, from Shell Overseas Investment B.V., which is a wholly-owned subsidiary of Shell PLC.

see more..

Aditya Birla Group to buy Shell's Sprng Energy for Rs 17,200 Crore

14 Jul 2026 | 6:02 PM

Mumbai, Jul 14 (UNI) Aditya Birla Renewables Limited (ABRen), a subsidiary of Grasim Industries Ltd, has officially announced the signing of a definitive agreement to acquire 100% equity shares and securities of Solenergi Power Private Limited, which owns the Sprng Energy group of companies, from Shell Overseas Investment B.V., which is a wholly-owned subsidiary of Shell PLC.
According to the official statement, this transaction is amongst the largest acquisitions in India’s renewable energy sector both by value and scale.

see more..